SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-019337
Filing Date
2024-04-30
Accepted
2024-04-30 16:02:29
Documents
14
Period of Report
2024-04-24
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K sgmo-20240424.htm   iXBRL 8-K 30402
  Complete submission text file 0001628280-24-019337.txt   184404

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20240424.xsd EX-101.SCH 2197
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT sgmo-20240424_def.xml EX-101.DEF 14822
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20240424_lab.xml EX-101.LAB 26294
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20240424_pre.xml EX-101.PRE 15464
17 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20240424_htm.xml XML 2714
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

IRS No.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 24897000
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)